Coherus Oncology (CHRS) Q2 FY26 earnings call

Coherus Oncology is navigating an exciting period of pipeline data maturation for its Tagmokitug and Casdozokitug programs, with key readouts anticipated in the second half of the year. Concurrently, the company demonstrated strong commercial execution for LOQTORZI, achieving significant sales growth and new patient starts. Post-biosimilar divestiture, Coherus has substantially reduced its cost structure and liabilities, maintaining sufficient funding through upcoming data milestones.